As presented at the National Niemann-Pick Disease Foundation 26th Annual Family Conference by CTD Holdings' Vice President for Medical Affairs, Dr. Sharon Hrynkow on August 3rd, 2018. Under the leadership of Dr. Darius Adams, CTD is setting up a second US trial site for its clinical trial, "A Phase I study to evaluate the single and multiple-dose pharmacokinetics of intravenous Trappsol(R) Cyclo(TM) (HP-b-CD) in patients with Niemann-Pick disease type C (NPC-1) and the effects of dosing upon biomarkers of NPC disease."
Safe Harbor Statement:
This infomration contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Source: CTD Holdings, Inc.